company background image
ADMS

Adamas PharmaceuticalsNasdaqGM:ADMS Stock Report

Market Cap

US$368.4m

7D

0.2%

1Y

130.7%

Updated

25 Oct, 2021

Data

Company Financials +
ADMS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health1/6
Dividends0/6

ADMS Overview

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Adamas Pharmaceuticals
Historical stock prices
Current Share PriceUS$8.05
52 Week HighUS$2.96
52 Week LowUS$9.15
Beta2.6
1 Month Change64.96%
3 Month Change67.71%
1 Year Change130.66%
3 Year Change-51.48%
5 Year Change-41.41%
Change since IPO-42.54%

Recent News & Updates

Aug 04
Is Adamas Pharmaceuticals (NASDAQ:ADMS) Using Too Much Debt?

Is Adamas Pharmaceuticals (NASDAQ:ADMS) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Jul 06

Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth

Adamas Pharmaceuticals reported their Q1 earnings with a slight beat on EPS and a slight miss on revenue. GOCOVRI continues to report impressive growth despite a lackluster launch. Despite the commercial progress, the ADMS share price remains suppressed. It looks as if the Street is waiting to see if and when the company will clear a profit. I reloaded on top of my core position in hopes Adamas will break even around 2024, but I willing to unload due to the ticker being in purgatory.

Shareholder Returns

ADMSUS BiotechsUS Market
7D0.2%2.7%1.9%
1Y130.7%18.8%33.4%

Return vs Industry: ADMS exceeded the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: ADMS exceeded the US Market which returned 30.3% over the past year.

Price Volatility

Is ADMS's price volatile compared to industry and market?
ADMS volatility
ADMS Beta2.6
Industry Beta0.98
Market Beta1

Stable Share Price: ADMS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: ADMS's weekly volatility has increased from 14% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000138Neil McFarlanehttps://www.adamaspharma.com

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy.

Adamas Pharmaceuticals Fundamentals Summary

How do Adamas Pharmaceuticals's earnings and revenue compare to its market cap?
ADMS fundamental statistics
Market CapUS$368.42m
Earnings (TTM)-US$55.11m
Revenue (TTM)US$82.47m

4.5x

P/S Ratio

-6.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADMS income statement (TTM)
RevenueUS$82.47m
Cost of RevenueUS$2.00m
Gross ProfitUS$80.47m
ExpensesUS$135.58m
Earnings-US$55.11m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.20
Gross Margin97.58%
Net Profit Margin-66.82%
Debt/Equity Ratio-3,216.2%

How did ADMS perform over the long term?

See historical performance and comparison

Valuation

Is Adamas Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ADMS ($8.05) is trading below our estimate of fair value ($47.55)

Significantly Below Fair Value: ADMS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ADMS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ADMS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADMS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADMS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Future Growth

How is Adamas Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

65.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADMS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ADMS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ADMS's is expected to become profitable in the next 3 years.

Revenue vs Market: ADMS's revenue (15.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: ADMS's revenue (15.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADMS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Adamas Pharmaceuticals performed over the past 5 years?

-0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADMS is currently unprofitable.

Growing Profit Margin: ADMS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADMS is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare ADMS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ADMS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Adamas Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ADMS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ADMS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADMS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ADMS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Adamas Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADMS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADMS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADMS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADMS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADMS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Neil McFarlane (48 yo)

2.08yrs

Tenure

US$1,692,941

Compensation

Mr. Neil F. Mcfarlane serves as Chief Executive Officer and Director of Adamas Pharmaceuticals, Inc. since September 16, 2019. Mr. Mcfarlane served as Chief Operating Officer of Retrophin, Inc. since Augus...


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD1.69M) is about average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ADMS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: ADMS's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.8%.


Top Shareholders

Company Information

Adamas Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Adamas Pharmaceuticals, Inc.
  • Ticker: ADMS
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$368.424m
  • Shares outstanding: 45.77m
  • Website: https://www.adamaspharma.com

Number of Employees


Location

  • Adamas Pharmaceuticals, Inc.
  • 1900 Powell Street
  • Suite 1000
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 23:21
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.